1	JAIL DRUG TREATMENT PILOT PROGRAM		
2	2020 GENERAL SESSION		
3	STATE OF UTAH		
4	Chief Sponsor: Carol Spackman Moss		
5	Senate Sponsor:		
6			
7	LONG TITLE		
8	General Description:		
9	This bill creates a pilot program to provide treatment to incarcerated individuals who		
10	are addicted to certain substances.		
11	Highlighted Provisions:		
12	This bill:		
13	defines terms;		
14	 creates a pilot program to administer Naltrexone treatment to certain individuals 		
15	who suffer from alcohol or opiate addiction;		
16	 provides that the Utah Division of Substance Abuse and Mental Health shall 		
17	administer the program; and		
18	 provides minimum qualifications for a county or an individual seeking to participate 		
19	in the program.		
20	Money Appropriated in this Bill:		
21	None		
22	Other Special Clauses:		
23	None		
24	Utah Code Sections Affected:		
25	AMENDS:		



	63I-2-262, as last amended by Laws of Utah 2019, Chapters 136 and 440
ENA	62A-15-118, Utah Code Annotated 1953
Be it	enacted by the Legislature of the state of Utah:
	Section 1. Section 62A-15-118 is enacted to read:
	62A-15-118. County Jail Drug Treatment Pilot Program.
	(1) As used in this section:
	(a) "Federally qualified health center" means the same as that term is defined in 42
<u>U.S.C</u>	C. Sec. 1395x.
	(b) "Division" means the Division of Substance Abuse and Mental Health.
	(c) "Program" means the County Jail Drug Treatment Pilot Program created in this
section	on.
	(2) There is created the County Jail Drug Treatment Pilot Program for the purpose of
provi	ding Naltrexone treatment to individuals who are or were recently incarcerated at a county
jail.	
	(3) (a) The division shall administer the program in accordance with this section.
	(b) The division may, upon application by a county in accordance with Subsection (4),
appro	eve the county to participate in the program if:
	(i) the county has a population of 150,000 or less;
	(ii) a federally qualified health center is located within the county;
	(iii) one or more federally qualified health centers located in the county agree to
partic	cipate in the program in conjunction with the county; and
	(iv) the county jail within the county has access to a health professional licensed to
draw	blood, administer prescription drugs by injection, and offer medical advice.
	(c) In accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act, the
divisi	on shall establish a process by which the division:
	(i) reviews and approves an application for participation in the program;
	(ii) coordinates with one or more Naltrexone providers to assist participating counties
in ob	taining Naltrexone;
	(iii) applies for grants that provide funding to support the administration of Naltrexone

03-12-20 3:13 PM

5/	to current or former qualifying inmates; and
58	(iv) oversees the administration of the program.
59	(4) To participate in the program, a county shall submit an application to the division
60	no later than April 1, 2021, that includes:
61	(a) contact information for the individuals who will oversee and implement the
62	program at:
63	(i) the county;
64	(ii) the county jail; and
65	(iii) the federally qualified health facility; and
66	(b) the application materials required by the division.
67	(5) An individual incarcerated at a county jail in a participating county may elect to
68	receive Naltrexone treatment under the program, if the individual:
69	(a) suffers an alcohol or opiate addiction;
70	(b) is of sufficient health to receive Naltrexone treatment, as determined by a qualified
71	health professional; and
72	(c) is currently incarcerated at the county jail and the county jail will have adequate
73	time to screen and advise the individual, in accordance with Subsection (7), before the county
74	jail releases the individual from incarceration.
75	(6) The Naltrexone treatment described in Subsection (5)(b) shall, to the extent
76	medically advisable, consist of:
77	(a) one injection administered at the county jail by a health professional, licensed as
78	described in Subsection (3)(b)(iv), within seven days before the day on which the county jail
79	releases the individual from incarceration; and
80	(b) five additional injections administered by a health professional, licensed as
81	described in Subsection (3)(b)(iv) and employed by a federally qualified health center, on a
82	monthly basis following the individual's release from incarceration.
83	(7) Before the first injection described in Subsection (6)(a), a health professional who
84	is licensed as described in Subsection (3)(b)(iv), shall:
85	(a) assess the individual's health to ensure the Naltrexone treatment is safe for the
86	individual; and
87	(b) fully advise the individual of all potential side effects and risks associated with the

88	Naltrexone treatment.
89	(8) (a) Before an individual receives the Naltrexone treatment under the program, the
90	individual shall agree to:
91	(i) attend a monthly appointment at a designated federally qualified health center to
92	receive a Naltrexone injection for five consecutive months; and
93	(ii) attend counseling as ordered by the court.
94	(b) A violation of the agreement described in Subsection (8)(a) may disqualify the
95	individual from participation in the program.
96	(9) If practicable, the participating county shall provide a case worker to oversee and
97	assist the individuals participating in the program.
98	(10) Naltrexone treatment administered under this program shall be funded or provided
99	<u>by:</u>
100	(a) available federal funding or grants;
101	(b) grants of Naltrexone provided by a non-governmental organization;
102	(c) an individual receiving Naltrexone treatment, through the individual's independent
103	financing or the individual's health benefit plan, as defined in Section 31A-1-301; or
104	(d) any other governmental or non-governmental organization that provides funding
105	<u>for:</u>
106	(i) treatment to an individual participating in the program; or
107	(ii) the program generally.
108	(11) The program begins on July 1, 2021, and ends on December 30, 2026.
109	Section 2. Section 63I-2-262 is amended to read:
110	63I-2-262. Repeal dates Title 62A.
111	(1) Subsection 62A-5-103.1(6) is repealed January 1, 2023.
112	(2) Section 63A-15-118 is repealed December 31, 2026.